FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039725146> ?p ?o ?g. }

• W2039725146 endingPage "36" @default.
• W2039725146 startingPage "25" @default.
• W2039725146 abstract "To review the impact of anemia/tumor hypoxemia on the quality of life and survival in cancer patients, and to assess the problems associated with the correction of this difficulty.MEDLINE searches were performed to find relevant literature regarding anemia and/or tumor hypoxia in cancer patients. Articles were evaluated in order to assess the epidemiology, adverse patient effects, anemia correction guidelines, and mechanisms of hypoxia-induced cancer cell growth and/or therapeutic resistance. Past and current clinical studies of radiosensitization via tumor oxygenation/hypoxic cell sensitization were reviewed. All clinical studies using multi-variate analysis were analyzed to show whether or not anemia and/or tumor hypoxemia affected tumor control and patient survival. Articles dealing with the correction of anemia via transfusion and/or erythropoietin were reviewed in order to show the impact of the rectification on the quality of life and survival of cancer patients.Approximately 40-64% of patients presenting for cancer therapy are anemic. The rate of anemia rises with the use of chemotherapy, radiotherapy, and hormonal therapy for prostate cancer. Anemia is associated with reductions both in quality of life and survival. Tumor hypoxemia has been hypothesized to lead to tumor growth and resistance to therapy because it leads to angiogenesis, genetic mutations, resistance to apoptosis, and a resistance to free radicals from chemotherapy and radiotherapy. Nineteen clinical studies of anemia and eight clinical studies of tumor hypoxemia were found that used multi-variate analysis to determine the effect of these conditions on the local control and/or survival of cancer patients. Despite differing definitions of anemia and hypoxemia, all studies have shown a correlation between low hemoglobin levels and/or higher amounts of tumor hypoxia with poorer prognosis. Radiosensitization through improvements in tumor oxygenation/hypoxic cell sensitization has met with limited success via the use of hyperbaric oxygen, electron-affinic radiosensitizers, and mitomycin. Improvements in tumor oxygenation via the use of carbogen and nicotinamide, RSR13, and tirapazamine have shown promising clinical results and are all currently being tested in Phase III trials. The National Comprehensive Cancer Network (NCCN) guidelines recommend transfusion or erythropoietin for symptomatic patients with a hemoglobin of 10-11 g/dl and state that erythropoietin should strongly be considered if hemoglobin falls to less than 10 g/dl. These recommendations were based on studies that revealed an improvement in the quality of life of cancer patients, but not patient survival with anemia correction. Phase III studies evaluating the correction of anemia via erythropoietin have shown mixed results with some studies reporting a decrease in patient survival despite an improvement in hemoglobin levels. Diverse functions of erythropoietin are reviewed, including its potential to inhibit apoptosis via the JAK2/STAT5/BCL-X pathway. Correction of anemia by the use of blood transfusions has also shown a decrement in patient survival, possibly through inflammatory and/or immunosuppressive pathways.Anemia is a prevalent condition associated with cancer and its therapies. Proper Phase III trials are necessary to find the best way to correct anemia for specific patients. Future studies of erythropoietin must evaluate the possible anti-apoptotic effects by directly assessing the tumor for erythropoietin receptors or the presence of the JAK2/STAT5/BCL-X pathway. Due to the ability of transfusions to cause immunosuppression, most probably through inflammatory pathways, it may be best to study the effects of transfusion with the prolonged use of anti-inflammatory medications." @default.
• W2039725146 created "2016-06-24" @default.
• W2039725146 creator A5073148366 @default.
• W2039725146 creator A5081655990 @default.
• W2039725146 date "2005-09-01" @default.
• W2039725146 modified "2023-09-25" @default.
• W2039725146 title "Anemia, tumor hypoxemia, and the cancer patient" @default.
• W2039725146 cites W111014377 @default.
• W2039725146 cites W1868704956 @default.
• W2039725146 cites W1885881044 @default.
• W2039725146 cites W189180901 @default.
• W2039725146 cites W1931089045 @default.
• W2039725146 cites W1956256739 @default.
• W2039725146 cites W1974106801 @default.
• W2039725146 cites W1982281000 @default.
• W2039725146 cites W1985883143 @default.
• W2039725146 cites W1987970382 @default.
• W2039725146 cites W1997971145 @default.
• W2039725146 cites W1999601388 @default.
• W2039725146 cites W2002189627 @default.
• W2039725146 cites W2002655092 @default.
• W2039725146 cites W2002782759 @default.
• W2039725146 cites W2013436421 @default.
• W2039725146 cites W2015276413 @default.
• W2039725146 cites W2016026738 @default.
• W2039725146 cites W2020368146 @default.
• W2039725146 cites W2021006272 @default.
• W2039725146 cites W2022342238 @default.
• W2039725146 cites W2031890910 @default.
• W2039725146 cites W2040641457 @default.
• W2039725146 cites W2042312061 @default.
• W2039725146 cites W2042586826 @default.
• W2039725146 cites W2043702533 @default.
• W2039725146 cites W2052386670 @default.
• W2039725146 cites W2060802775 @default.
• W2039725146 cites W2063741207 @default.
• W2039725146 cites W2064419187 @default.
• W2039725146 cites W2066448961 @default.
• W2039725146 cites W2069900690 @default.
• W2039725146 cites W2072463499 @default.
• W2039725146 cites W2072839085 @default.
• W2039725146 cites W2074044281 @default.
• W2039725146 cites W2079109507 @default.
• W2039725146 cites W2080141853 @default.
• W2039725146 cites W2085492571 @default.
• W2039725146 cites W2087604644 @default.
• W2039725146 cites W2087704303 @default.
• W2039725146 cites W2088561350 @default.
• W2039725146 cites W2091061603 @default.
• W2039725146 cites W2093109941 @default.
• W2039725146 cites W2093666912 @default.
• W2039725146 cites W2098002323 @default.
• W2039725146 cites W2099268944 @default.
• W2039725146 cites W2099933670 @default.
• W2039725146 cites W2100053954 @default.
• W2039725146 cites W2102546064 @default.
• W2039725146 cites W2105246546 @default.
• W2039725146 cites W2107260099 @default.
• W2039725146 cites W2111959414 @default.
• W2039725146 cites W2114380559 @default.
• W2039725146 cites W2116554142 @default.
• W2039725146 cites W2116661176 @default.
• W2039725146 cites W2118477533 @default.
• W2039725146 cites W2125714271 @default.
• W2039725146 cites W2130864435 @default.
• W2039725146 cites W2132218438 @default.
• W2039725146 cites W2132382162 @default.
• W2039725146 cites W2138181551 @default.
• W2039725146 cites W2146353390 @default.
• W2039725146 cites W2148734088 @default.
• W2039725146 cites W2149982213 @default.
• W2039725146 cites W2152370760 @default.
• W2039725146 cites W2153287843 @default.
• W2039725146 cites W2157816698 @default.
• W2039725146 cites W2158238360 @default.
• W2039725146 cites W2159933261 @default.
• W2039725146 cites W2165673197 @default.
• W2039725146 cites W2167388961 @default.
• W2039725146 cites W2168269450 @default.
• W2039725146 cites W2171908639 @default.
• W2039725146 cites W2172200669 @default.
• W2039725146 cites W2271870719 @default.
• W2039725146 cites W2316067769 @default.
• W2039725146 cites W2397324258 @default.
• W2039725146 cites W2409873891 @default.
• W2039725146 cites W4243359591 @default.
• W2039725146 cites W4253440008 @default.
• W2039725146 cites W4253684909 @default.
• W2039725146 cites W4296277331 @default.
• W2039725146 doi "https://doi.org/10.1016/j.ijrobp.2005.04.049" @default.
• W2039725146 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16111569" @default.
• W2039725146 hasPublicationYear "2005" @default.
• W2039725146 type Work @default.
• W2039725146 sameAs 2039725146 @default.
• W2039725146 citedByCount "133" @default.
• W2039725146 countsByYear W20397251462012 @default.
• W2039725146 countsByYear W20397251462013 @default.
• W2039725146 countsByYear W20397251462014 @default.

• next